RT Book, Section A1 Garg, Abhimanyu A2 Kang, Sewon A2 Amagai, Masayuki A2 Bruckner, Anna L. A2 Enk, Alexander H. A2 Margolis, David J. A2 McMichael, Amy J. A2 Orringer, Jeffrey S. SR Print(0) ID 1161324000 T1 Lipodystrophy T2 Fitzpatrick's Dermatology, 9e YR 2019 FD 2019 PB McGraw-Hill Education PP New York, NY SN 9780071837798 LK accessmedicine.mhmedical.com/content.aspx?aid=1161324000 RD 2024/03/28 AB AT-A-GLANCELipodystrophies are genetic or acquired disorders characterized by selective loss of body fat. The extent of fat loss determines the severity of associated metabolic complications such as diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and acanthosis nigricans.Four loci have been identified for the autosomal recessive congenital generalized lipodystrophy (CGL), namely, AGPAT2, BSCL2, CAV1, and CAVIN1.Five loci have been identified for autosomal dominant familial partial lipodystrophy (FPL), namely, LMNA, PPARG, AKT2, PLIN1, and ADRA2A.LIPE, CIDEC, PCYT1A, and RECQL2 are loci for autosomal recessive FPL, and LMNA and ZMPSTE24 are loci for mandibuloacral dysplasia-associated lipodystrophy.Molecular basis of many extremely rare forms of genetic lipodystrophies remains to be elucidated.The most prevalent variety of lipodystrophy develops after prolonged duration of protease inhibitor containing highly active antiretroviral therapy in HIV-infected patients.The acquired generalized lipodystrophy and acquired partial lipodystrophy are mainly autoimmune in origin.Localized lipodystrophies occur as a result of drug or vaccine injections, pressure, and panniculitis, as well as other unknown reasons.Current management includes cosmetic surgery and early identification and treatment of metabolic and other complications.Metreleptin replacement therapy is beneficial for treating metabolic complications in hypoleptinemic patients with generalized lipodystrophies.